Abstract
Background A 12-week-old female presented with neonatal diabetes. Insulin therapy alleviated the diabetes, but the patient showed marked motor and mental developmental delay. The patient underwent genetic evaluation at the age of 6 years, prompted by reports that mutations in the KCNJ11 gene caused neonatal diabetes.
Investigations Genomic sequencing of the ATP-sensitive potassium (KATP) channel gene KCNJ11 and in vitro functional analysis of the channel defect, and single-photon emission CT imaging before and after glibenclamide therapy.
Diagnosis Genetic evaluation revealed a missense mutation (His46Leu) in KCNJ11, which encodes the Kir6.2 subunit of the KATP channel, conferring reduced ATP sensitivity. Functional studies demonstrated that the mutant channels were strongly inhibited by the sulfonylurea tolbutamide.
Management Sulfonylurea (glibenclamide) treatment led to both improved glucose homeostasis and an increase in mental and motor function.
The case
A female infant presented with polydipsia, glucosuria, ketoacidosis (pH 7.09, −14 mmol/l base excess) and severe hyperglycemia (blood glucose 42.5 mmol/l [766 mg/dl]) 12 weeks after birth. C peptide was undetectable. Tests for islet cell autoantibodies and antibodies against glutamic acid decarboxylase 65 (GAD65), insulinoma-associated antigen 2 and insulin were negative. The patient had no family history of diabetes. She had a low birth weight (2,700 g) despite an unremarkable pregnancy and a normal gestational age. For the first 72 h after diagnosis of neonatal diabetes she was treated with intravenous insulin (2.1 U/kg, 1.5 U/kg and 1.2 U/kg body weight, for the first, second and third days, respectively). Subsequently, she received subcutaneous insulin therapy with multiple insulin injections daily (1.3 U/kg body weight daily). She had frequent episodes of hyperglycemia and hypoglycemia (blood glucose 1.1–24.8 mmol/l [19.8–446.8 mg/dl]) from the time of diabetes onset to the age of around 3 years, and experienced two severe hypoglycemic episodes (blood glucose 1.1 mmol/l [19.8 mg/dl] on each occasion), one at 2 years of age and one at 4 years of age. The first episode was associated with loss of consciousness following physical activity and the second with night-time hypoglycemia. On both occasions the patient was treated with glucagon (0.5 mg) and no hospitalization was needed. No further episodes of ketoacidosis were documented. The patient's level of hemoglobin A1c (HbA1c) averaged 6.9% between 6 months and 6 years of diabetes duration (see Supplementary Table 1 online).
The patient's motor and mental functions were normal at diabetes diagnosis, but at 12 months of age she was still unable to stand without support and her motor milestones were similar to those of a normally developing child aged 8–10 months. No specific neurological features were found and the native electroencephalogram was normal. Importantly, developmental delay was evident before the first hypoglycemic episode. At the age of 24 months, a pediatric neurological examination revealed muscle weakness and lower limb hypotonia. The patient's reflexes and sensation were normal.
The patient underwent genetic evaluation at the age of 6 years, following reports that mutations in the KCNJ11 gene (which encodes the ATP-sensitive potassium channel Kir6.2 subunit) caused neonatal diabetes.1,2 At this time, the patient reportedly fell down 10–15 times per week and had difficulty running. The falls were not associated with loss of consciousness or seizures, and an electroencephalogram was normal. Muscle weakness and hypotonia of the lower extremities were still present: muscle power was graded as 3–4 on a scale of 0–5 for muscle power assessment in a cooperative child. At this time the patient also had difficulty sustaining attention. Psychological examination revealed that she fulfilled seven criteria for inattention and eight criteria for hyperactivity–impulsivity according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) diagnostic criteria for attention deficit hyperactivity disorder (ADHD). She showed mental retardation (using the Wechsler Preschool and Primary Scale of Intelligence-revised [WPPSI-R] test), demonstrating an IQ of 57 and mental abilities similar to those of a normal child aged 42–48 months.
An MRI scan revealed no brain structural abnormalities (see Supplementary Figure 1 online). Single-photon emission computed tomography (SPECT) examination, however, showed a focal perfusion deficit in the left temporal cortex (Figure 1A). Cerebellar indices were calculated for semi-quantitative evaluation of SPECT scans (Figure 1C,D).
Sequencing of the patient's KCNJ11 gene using genomic DNA extracted from peripheral lymphocytes identified a novel heterozygous mutation, His46Leu (c137A>T) in Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (KATP) channel (Figure 2A,B).2 Genotype analysis confirmed the family relationships, and that the His46Leu mutation was not present in either parent. In vitro functional studies determined that the His46Leu mutation reduced KATP channel sensitivity to ATP, and that the mutant channels were strongly inhibited by the sulfonylurea tolbutamide (Figure 2E and Supplementary Information 1 online). On the basis of the genotype and the clinical features of neonatal diabetes plus developmental delay, the patient was given a diagnosis of intermediate DEND (developmental delay, epilepsy and neonatal diabetes) syndrome.
Glibenclamide treatment was initiated because of the observed sensitivity of the mutant KATP channel to sulfonylureas in studies carried out in vitro. The initial dose was 0.1 mg/kg body weight daily, divided into three doses (see Supplementary Information 1 online), and this was gradually increased. The insulin dose was reduced concomitantly. During the transition period, a transitory diarrhea (lasting less than 3 days) without pyrexia was noted (as reported previously in other patients).3 Insulin was discontinued 1 month after initiating the transition to glibenclamide and good diabetes control (HbA1c level of 5.9% 4 months after initiation of glibenclamide therapy) was obtained with a sulfonylurea dose of 0.81 mg/kg body weight daily. The dose of glibenclamide was subsequently reduced and 10 months after transition the patient required only 0.62 mg/kg body weight glibenclamide daily. No hypoglycemia has been reported in the patient since she started on glibenclamide.
Seven months after starting glibenclamide treatment a pediatric neurological examination was normal. The child no longer had running problems (she fell down infrequently less than twice a week) and showed considerable improvement in sustaining attention. She was able to draw simple pictures, write a few letters and digits and clean her teeth by herself, none of which was observed before drug therapy. She now fulfilled only three criteria for inattention and five for hyperactivity–impulsivity (DSM-IV diagnostic criteria for ADHD). Mental development assessment using the WPPSI-R test still showed mild mental retardation but her intelligence had improved (IQ 71).
A second SPECT examination performed 16 weeks after insulin was discontinued revealed that the focal perfusion deficit in the left temporal cortex observed in the initial examination was no longer present (Figure 1B). A significant decrease in the average cerebellar indices was also apparent (Figure 1C,D), indicative of an increase in cerebellar perfusion. Continuous glucose monitoring over 3 days before the second SPECT scan and during the examination did not reveal any fluctuations in blood glucose level (see Supplementary Figure 2 online).
Discussion of diagnosis
DEND syndrome is defined as developmental delay with epilepsy, muscle weakness and neonatal diabetes and is caused by mutations in the KATP channel subunits Kir6.2 (encoded by KCNJ11) or SUR1 (sulfonylurea receptor 1; encoded by ABCC8).2 Intermediate DEND syndrome (iDEND) is a less severe condition in which neonatal diabetes is accompanied by muscle weakness and developmental delay but not epilepsy.2 To date, two KCNJ11 mutations have been shown to cause iDEND in some but not all patients: 4 of 5 patients with Val59Met and 2 of 7 patients with Arg201Cys had iDEND.2,5,6 These patients were characterized by low birth weight (mean ∼2.5 kg; percentile for weight 0.8–2.4%) despite normal gestational age, neonatal diabetes (mean age at diagnosis 5–6 weeks), muscle weakness, and motor and mental developmental delay (see Supplementary Table 2 online).2,6
The symptoms of the patient discussed in this Case Study were consistent with iDEND, and a mutation in KCNJ11 was confirmed by sequencing this gene. Mutations in KCNJ11 that cause iDEND act by reducing the ability of cellular ATP to block to the KATP channel.1,2,7 As a consequence, the channel remains open when blood glucose levels rise, preventing insulin secretion.2 As the mutation (His46Leu) carried by this patient was novel, in vitro functional analysis was used to confirm that the mutation reduced KATP channel ATP sensitivity (Figure 2C,D and Supplementary Information 1 online).
Approximately 50% of patients with low birth weight who present with permanent neonatal diabetes within the first 6 months of life have mutations in KCNJ11 or ABCC8.2,6 Anti-islet autoantibodies are usually absent. These characteristics differentiate neonatal diabetes from type 1 diabetes, which presents later and in which autoantibodies are present. Neurological features are associated with some KCNJ11 and ABCC8 mutations,2,5,6 but the extent of impairment of neurological function can vary, so patients should be assessed by a neurologist for muscle weakness and motor and mental developmental delay as well as epilepsy. These children might walk and talk later than normal.
Treatment and management
Recent evidence has shown that patients with gain-of-function mutations in KCNJ11 can be successfully treated with sulfonylureas, which block open KATP channels.8 This treatment removes the necessity for daily insulin injections and markedly enhances glycemic control.3,4,5 Functional studies revealed that KATP channels heterozygous for the His46Leu mutation (as would be the case in the current patient) exhibit a marked sensitivity to inhibition by the sulfonylurea tolbutamide (Figure 2E). When tolbutamide causes a block of this magnitude, patients carrying the relevant KCNJ11 mutations generally respond well to sulfonylurea therapy.3 Consequently, sulfonylurea therapy was initiated in the patient presented here, resulting in improved glycemic control and a reduction in HbA1c levels.
Remediation of this patient's neurological symptoms and mental status suggests that glibenclamide blocks KATP channels in neurons enough to normalize electrical activity and transmitter release, as it presumably does in β-cells. The improvements in brain blood flow and in motor and mental function are consistent with the high density of KATP channels found in the cerebellum and cerebral cortex.9,10 The increase in blood flow observed in the SPECT scans is most likely to reflect an increase in neuronal activity, rather than a direct effect on vascular tissue, because β-cell and neuronal (Kir6.2–SUR1) KATP channels are more sensitive to glibenclamide block than are vascular (Kir6.2–SUR2B) KATP channels.11
As relatively good glycemic control was achieved before both SPECT examinations, it is unlikely that variability in glucose levels had a large impact on the SPECT images. This finding is consistent with a previous SPECT study of pediatric patients with type 1 diabetes, which found that perfusion of the cerebellum and temporal lobe differed little between those patients with well-controlled and those with poorly controlled diabetes, or between patients with diabetes and healthy subjects.12 Although we cannot exclude the possibility that the current patient's increased IQ score was attributable, at least in part, to the natural course of the disease, the magnitude of the response and the short time interval (10 months) between the two sets of WPPSI-R tests make this an unlikely scenario. It is possible that the observed increase in IQ was partly a result of the improvement in ADHD symptoms produced by glibenclamide.
A major difference between insulin therapy and sulfonylurea treatment is that the former only controls glucose homeostasis whereas sulfonylureas should block KATP channels in all tissues to which they have access, and, therefore, alleviate extrapancreatic problems. Although the extent to which sulfonylureas cross the blood–brain barrier is unknown in humans, limited penetrance has been documented in rodents.13 The improvements in mental and motor function, and in brain blood flow, observed in the patient in this case following glibenclamide treatment suggest that the drug is able to access the brain at concentrations sufficient to influence KATP channel activity.
Conclusions
This Case Study describes a novel KCNJ11 mutation, His46Leu, causing iDEND syndrome. Sulfonylurea (glibenclamide) therapy not only restored glucose homeostasis, but also alleviated some of the neurological symptoms associated with the patient's impaired CNS function. Good long-term glycemic control together with an improvement in motor function following glibenclamide treatment has recently been reported in a patient with iDEND,5 but the impact of this treatment on the CNS has not yet been documented. Here we show for the first time that CNS blood flow and function can be improved by sulfonylureas. This study is the first to report the use of SPECT to provide evidence of brain changes that correlate with mental and motor improvement following glibenclamide therapy. This finding does not, of course, prove a causal relationship between the changes in brain perfusion and psychomotor function.
This Case Study re-emphasizes the necessity of screening for KATP channel mutations in diabetes diagnosed before the age of 6 months, especially if developmental delay is also present. Furthermore, introduction of sulfonylurea treatment in patients carrying KATP channel mutations should be implemented as soon as possible, not only to improve glycemic control, but also to help alleviate neurological problems.
References
Gloyn AL et al. (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350: 1838–1849
Hattersley AT and Ashcroft FM (2005) Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 54: 2503–2513
Pearson ER et al. (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355: 467–477
Malecki MT et al. (2007) Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating mutations: evidence for improvement in insulin sensitivity. Diabetes Care 30: 147–149
Slingerland AS et al. (2006) Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 49: 2559–2563
Flanagan SE et al. (2006) Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49: 1190–1197
Proks P et al. (2004) Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA 101: 17539–17544
Gribble FM and Reimann F (2003) Sulphonylurea action revisited: the post-cloning era. Diabetologia 46: 875–891
Karschin C et al. (1997) Overlapping distribution of KATP channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. FEBS Lett 401: 59–64
Dunn-Meynell AA et al. (1998) Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 814: 41–54
Stephan D et al. (2006) Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular KATP channels. Diabetologia 49: 2039–2048
Salem MAK et al. (2002) Single photon emission tomography (SPECT) study of regional blood flow in normoalbuminuric children and adolescents with type 1 diabetes. Pediatr Diabetes 3: 155–162
Takanaga H et al. (1998) Efflux transport of tolbutamide across the blood–brain barrier. J Pharm Pharmacol 50: 1027–1033
Antcliff JF et al. (2005) Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. EMBO J 24: 229–239
Acknowledgements
We thank the patient and her referring clinicians. We thank Dr Peter Proks and Prof Jerzy Bodalski for critical discussion. Financial support was provided by the Wellcome Trust, the Royal Society, the European Union (Integrated Project EuroDia LSHM-CT- 2006-518153 in the Framework Programme 6 [FP6] of the European-Community) and the Polish Ministry of Education and Science (Grant No. 2 P0E 136 29). FM Ashcroft is a Royal Society Research Professor.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information 1
Description of methods and additional results and discussion. (DOC 63 kb)
Supplementary Figure 1
MRI scans reveal no structural abnormalities. (PPT 98 kb)
Supplementary Figure 2
Glucose variability in subcutaneous interstitial fluid measured over three days prior to the second SPECT scan and on the day of examination using a continuous glucose monitoring system (CGMS). (PPT 43 kb)
Supplementary Figure 3
The H46L mutation did not alter the density of channels in the plasma membrane. (PPT 201 kb)
Supplementary Figure 4
The H46L mutation reduces KATP channel ATP sensitivity. (PPT 87 kb)
Supplementary Table 1
HbA1c levels before and after glibenclamide therapy. (DOC 29 kb)
Supplementary Table 2
Comparison of clinical phenotypes of patients with intermediate DEND syndrome. (DOC 38 kb)
Supplementary Table 3
Properties of wild-type and mutant KATP channels. (DOC 31 kb)
Rights and permissions
About this article
Cite this article
Mlynarski, W., Tarasov, A., Gach, A. et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Rev Neurol 3, 640–645 (2007). https://doi.org/10.1038/ncpneuro0640
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0640
This article is cited by
-
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Die Diabetologie (2023)
-
Empirical sulphonylurea in neonatal diabetes: results from a tertiary care center
International Journal of Diabetes in Developing Countries (2022)
-
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Die Diabetologie (2022)
-
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Der Diabetologe (2021)
-
New insights into KATP channel gene mutations and neonatal diabetes mellitus
Nature Reviews Endocrinology (2020)